Osborn Neal K, Ahlquist David A
Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
Gastroenterology. 2005 Jan;128(1):192-206. doi: 10.1053/j.gastro.2004.10.041.
Assay of molecular markers in stool represents a promising noninvasive approach to screen colorectal cancer. Given that neoplasms exfoliate abundantly into the lumen and that DNA recovered from stool can be assayed with sensitive techniques, there is a strong biologic rationale to pursue this emerging technology. A challenge with DNA-based testing relates to the selection of markers. Because of the molecular heterogeneity of cancer, no single marker has yielded perfect sensitivity. Several combinations of markers in early stool assays have produced high detection rates of both colorectal cancer and advanced adenomas in selected patient groups, but observations from large representative populations are lacking at present. Potential expanded applications of stool DNA testing include detection of supracolonic aerodigestive cancers and of dysplasia in inflammatory bowel disease. Further marker discovery and technologic refinements should translate into improved test performance and fuel a continued evolution with this screening approach.
粪便中分子标志物的检测是一种很有前景的非侵入性结直肠癌筛查方法。鉴于肿瘤大量脱落至肠腔,且从粪便中回收的DNA可用敏感技术进行检测,因此有充分的生物学依据来探索这项新兴技术。基于DNA检测的一个挑战与标志物的选择有关。由于癌症的分子异质性,没有单一标志物能产生完美的敏感性。早期粪便检测中几种标志物组合在特定患者群体中对结直肠癌和晚期腺瘤均产生了较高的检出率,但目前缺乏来自大型代表性人群的观察结果。粪便DNA检测潜在的扩展应用包括检测结肠上消化呼吸道癌症和炎症性肠病中的发育异常。进一步的标志物发现和技术改进应能转化为检测性能的提升,并推动这种筛查方法的持续发展。